Certara (NASDAQ:CERT) Updates FY 2026 Earnings Guidance

Certara (NASDAQ:CERT) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 0.350-0.410 for the period, compared to the consensus estimate of 0.360. The company issued revenue guidance of $395.0 million-$405.0 million, compared to the consensus revenue estimate of $398.9 million.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on CERT shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Certara in a research note on Friday, May 29th. Craig Hallum dropped their price target on Certara from $10.00 to $8.00 and set a “hold” rating for the company in a report on Tuesday, May 12th. BMO Capital Markets lowered their price objective on Certara from $7.00 to $6.00 and set a “market perform” rating on the stock in a research report on Tuesday, May 12th. KeyCorp reduced their target price on shares of Certara from $10.00 to $8.00 and set an “overweight” rating for the company in a research report on Monday, April 13th. Finally, Morgan Stanley decreased their price target on shares of Certara from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Certara has an average rating of “Hold” and an average target price of $8.85.

Certara Stock Performance

CERT opened at $6.36 on Tuesday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.88 and a current ratio of 1.88. Certara has a 52-week low of $4.45 and a 52-week high of $13.88. The firm has a market cap of $989.39 million, a P/E ratio of -63.60 and a beta of 1.49. The business’s fifty day moving average is $5.58 and its 200-day moving average is $6.90.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Monday, May 11th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.02). Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.The firm had revenue of $106.92 million for the quarter, compared to the consensus estimate of $106.13 million. During the same period in the prior year, the company earned $0.14 EPS. The company’s revenue for the quarter was up .8% compared to the same quarter last year. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. Sell-side analysts expect that Certara will post 0.24 EPS for the current fiscal year.

Institutional Trading of Certara

Several large investors have recently bought and sold shares of CERT. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Certara by 2,733.3% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock valued at $26,000 after purchasing an additional 2,870 shares during the last quarter. Osaic Holdings Inc. boosted its position in Certara by 50.7% in the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after buying an additional 1,175 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Certara by 499.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock worth $69,000 after buying an additional 4,930 shares during the last quarter. Canada Pension Plan Investment Board acquired a new position in shares of Certara during the second quarter worth $83,000. Finally, Engineers Gate Manager LP acquired a new position in shares of Certara during the fourth quarter worth $92,000. 73.96% of the stock is owned by institutional investors and hedge funds.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.